Alzheimers disease
Conditions
Interventions
Clinical Cohort and Community Cohort:None
Sponsors
Daping Hospital, the Third Military Medical University
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: Clinical Cohort 1. Aged 50 years or above; 2. Voluntary participation in this study, with signed informed consent from the participant and/or their legal guardian. This includes: (1) 1,000 patients with Aß(+) AD meeting the AA (2024) diagnostic criteria; (2) 1,000 patients with MCI due to AD meeting the AA (2024) diagnostic criteria; (3) 1,000 patients with preclinical AD meeting the AA (2024) diagnostic criteria; (4) 500 cognitively normal controls without cognitive impairment, including: 1). Individuals with subjective memory complaints (SMC); 2). Individuals without subjective memory complaints (NMC); (5) 500 patients with other types (non-AD) of MCI; (6) 500 patients with other types (non-AD) of dementia; (7) 500 patients with other neurodegenerative diseases, such as Parkinson's disease or Huntington's disease. Community Cohort 1.Aged 50 years or above, both male and female; 2.In good general health, without interference from other diseases expected during the study period; 3.Visual and auditory acuity (including corrected vision and hearing) sufficient to undergo neuropsychological testing; 4.Participants are not pregnant, lactating, or of childbearing potential (i.e., women must be postmenopausal for at least two years or have undergone sterilization surgery); 5.Willingness and ability to participate in longitudinal biomarker and imaging studies; 6.Consent to blood collection for biomarker testing; 7.Consent to share genomic data and biomarker samples; 8.Voluntary participation in this study, with signed informed consent from the participant and/or their legal guardian.
Exclusion criteria
Exclusion criteria: 1. Individuals with other significant neuropsychiatric disorders indicated by the Hamilton Depression/Anxiety Rating Scale, Neuropsychiatric Inventory (NPI), or medical history; 2. Central nervous system infections, head trauma, epilepsy, multiple sclerosis, toxic-metabolic diseases, intracranial tumors, etc.; 3. Systemic infections; severe cardiac diseases such as coronary heart disease, cardiac insufficiency, atrial fibrillation; severe hepatic or renal insufficiency; severe hematological diseases, coagulation disorders; advanced malignant tumors, etc.; 4. Allergy to 11C-PIB, FDG, AV45, AV-1, MK6240 tracers or gadolinium-based contrast agents; 5.Violation of study rules, poor compliance, or refusal to participate in this project..
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Aß42;pTau217;Activity of Daily Living Scale Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence;Aß-PET;Tau-PET;Aß40;Mini-Mental State Examination;Montreal Cognitive Assessment Score;Clinical Dementia Rating Scale Score;Ascertain Dementia 8-item Questionnaire; Community Screening Instrument for Dementia; | — |
Countries
China
Contacts
Public ContactWang Yanjiang
Daping Hospital, the Third Military Medical University
Outcome results
None listed